Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 487 articles:
HTML format



Single Articles


    October 2021
  1. ZELADA-RIOS L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaque-Chunga C, et al
    Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases.
    J Neuroimmunol. 2021;359:577674.
    PubMed     Abstract available


    September 2021
  2. OO WM, Giri P, de Souza A
    AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?
    J Neuroimmunol. 2021;360:577719.
    PubMed     Abstract available


  3. SAMUDRALWAR RD
    Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.
    J Neuroimmunol. 2021;358:577660.
    PubMed    


  4. GHOSH R, Dubey S, Mandal A, Ray BK, et al
    Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
    J Neuroimmunol. 2021;358:577655.
    PubMed     Abstract available


  5. PAGENKOPF C, Sudmeyer M
    A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
    J Neuroimmunol. 2021;358:577606.
    PubMed     Abstract available


  6. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available


  7. PHILLIPS O, Tubre T, Lorenco H, Batish SD, et al
    Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and critical review of the history of autoimmune anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2021;360:577716.
    PubMed     Abstract available


    August 2021
  8. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available


  9. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available


  10. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available


  11. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available


  12. QIAO X, Wang H, Lu L, Chen J, et al
    Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice.
    J Neuroimmunol. 2021;357:577620.
    PubMed     Abstract available


  13. CHAKRABORTY AP, Pandit A, Ray BK, Mukherjee A, et al
    Capgras syndrome and confabulation unfurling anti NMDAR encephalitis with classical papillary thyroid carcinoma: First reported case.
    J Neuroimmunol. 2021;357:577611.
    PubMed     Abstract available


  14. EQUIZA J, Rodriguez-Antiguedad J, Campo-Caballero D, Iruzubieta P, et al
    Autoimmune GFAP astrocytopathy presenting with remarkable CNS hyperexcitability and oculogyric crises.
    J Neuroimmunol. 2021;359:577695.
    PubMed     Abstract available


  15. COSSU D, Yokoyama K, Sato S, Noda S, et al
    PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2021;359:577694.
    PubMed     Abstract available


  16. MIN YG, Ju W, Ha YE, Ban JJ, et al
    Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    J Neuroimmunol. 2021;359:577691.
    PubMed     Abstract available


  17. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available


    July 2021
  18. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available


  19. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available


  20. LAI QL, Cai MT, Zheng Y, Zhang TY, et al
    Seasonal variation in autoimmune encephalitis: A multi-center retrospective study.
    J Neuroimmunol. 2021;359:577673.
    PubMed     Abstract available


  21. YAO Y, Li X, Lin J, Zhang X, et al
    Thymoma-associated autoimmune encephalitis with positive Titin antibodies: A case report.
    J Neuroimmunol. 2021;358:577670.
    PubMed     Abstract available


  22. GUO L, Ren H, Fan S, Guan H, et al
    Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report.
    J Neuroimmunol. 2021;359:577667.
    PubMed     Abstract available


  23. WANG J, Yan C, Zhao Z, Chen H, et al
    Sexual dysfunction in patients with myasthenia gravis.
    J Neuroimmunol. 2021;358:577669.
    PubMed     Abstract available


  24. CAPARO-ZAMALLOA C, Alvarez-Toledo K, Yamunaque-Chunga C, Castro-Suarez S, et al
    Autoimmune neurology: Co-occurrence of anti-NMDAR encephalitis and anti-MOG associated disease, report of a case.
    J Neuroimmunol. 2021;358:577663.
    PubMed     Abstract available


  25. LOCKHART A, Boers P
    Paraneoplastic neurologic syndromes with multiple neural autoantibodies: A report of two cases.
    J Neuroimmunol. 2021;358:577665.
    PubMed     Abstract available


  26. LI R, Wang J, Li C, Liu X, et al
    Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.
    J Neuroimmunol. 2021;356:577604.
    PubMed     Abstract available


  27. DINOTO A, Cheli M, Bratina A, Sartori A, et al
    Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
    J Neuroimmunol. 2021;356:577586.
    PubMed     Abstract available


  28. NARESH K, Miraclin TA, Prabhakar AT, Mathew V, et al
    Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica.
    J Neuroimmunol. 2021;356:577581.
    PubMed     Abstract available


  29. WONG CK, Hor JY, Loo YP, Heng HS, et al
    High incidence of NMDAR encephalitis among Austronesians: A population-based study in Sabah, Malaysia.
    J Neuroimmunol. 2021;356:577584.
    PubMed     Abstract available


  30. HONGO Y, Kaida K, Komuta Y, Takazaki H, et al
    Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing.
    J Neuroimmunol. 2021;356:577580.
    PubMed     Abstract available


  31. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available


  32. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available


  33. CORTES-VICENTE E, Alvarez-Velasco R, Illa I, Gallardo E, et al
    Comment to "Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis".
    J Neuroimmunol. 2021;358:577659.
    PubMed    


  34. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available


  35. KHANMOHAMMADI S, Malekpour M, Jabbari P, Rezaei N, et al
    Genetic basis of Guillain-Barre syndrome.
    J Neuroimmunol. 2021;358:577651.
    PubMed     Abstract available


    June 2021
  36. MOSTAFA GA, Meguid NA, Shehab AAS, Elsaeid A, et al
    Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity.
    J Neuroimmunol. 2021;358:577638.
    PubMed     Abstract available


  37. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available


  38. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available


  39. UZAWA A, Akamine H, Kojima Y, Ozawa Y, et al
    High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis.
    J Neuroimmunol. 2021;358:577634.
    PubMed     Abstract available


  40. FINSTERER J
    Steroid-responsive, transverse myelitis is a known complication of COVID-19.
    J Neuroimmunol. 2021;355:577566.
    PubMed    


  41. LEE JK, Kwon S, Han JH, Yoon SE, et al
    Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
    J Neuroimmunol. 2021;355:577564.
    PubMed     Abstract available


  42. GOVIL-DALELA T, Datta I, Williams M
    Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib.
    J Neuroimmunol. 2021;355:577565.
    PubMed     Abstract available


  43. SON H, Lee WJ, Moon J, Yoon S, et al
    Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    J Neuroimmunol. 2021;355:577551.
    PubMed     Abstract available


  44. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available


  45. FINSTERER J, Ghosh R
    Dimensions of SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neuroimmunol. 2021;357:577626.
    PubMed    


  46. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available


    May 2021
  47. GRISANTI SG, Franciotta D, Garnero M, Zuppa A, et al
    A case series of parainfectious Guillain-Barre syndrome linked to influenza A (H1N1) virus infection.
    J Neuroimmunol. 2021;357:577605.
    PubMed     Abstract available


  48. MANOUCHEHRI N, Guisso DR, Hussain RZ, Minassian BA, et al
    The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo.
    J Neuroimmunol. 2021;354:577544.
    PubMed     Abstract available


  49. WANG T, Wang B, Zeng Z, Li H, et al
    Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
    J Neuroimmunol. 2021;354:577527.
    PubMed     Abstract available


  50. FINSTERER J, Scorza FA, Scorza CA, Fiorini AC, et al
    Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.
    J Neuroimmunol. 2021;357:577609.
    PubMed    


  51. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available


  52. ROTOLO RA, Demuro J, Drummond G, Little C, et al
    Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577603.
    PubMed     Abstract available


  53. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available


  54. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available


  55. ZULIANI L, Marangoni S, De Gaspari P, Rosellini I, et al
    Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics.
    J Neuroimmunol. 2021 May 1:577598. doi: 10.1016/j.jneuroim.2021.577598.
    PubMed     Abstract available


    April 2021
  56. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    PubMed    


  57. DOPPLER K, Hemprich A, Haarmann A, Brecht I, et al
    Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis.
    J Neuroimmunol. 2021;356:577588.
    PubMed     Abstract available


  58. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available


  59. MASI G, Spagni G, Campetella L, Monte G, et al
    Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis.
    J Neuroimmunol. 2021;356:577601.
    PubMed     Abstract available


  60. PAPRI N, Hayat S, Mohammed A, Afsar MNA, et al
    Guillain-Barre syndrome associated with SARS-CoV-2 infection: A case report with long term follow up.
    J Neuroimmunol. 2021;356:577590.
    PubMed     Abstract available


  61. HOU H, Sun Y, Miao J, Gao M, et al
    Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577583.
    PubMed     Abstract available


  62. SHEIKH AB, Chourasia PK, Javed N, Chourasia MK, et al
    Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.
    J Neuroimmunol. 2021;355:577577.
    PubMed     Abstract available


  63. MORENO-ESCOBAR MC, Kataria S, Khan E, Subedi R, et al
    Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature.
    J Neuroimmunol. 2021;353:577523.
    PubMed     Abstract available


  64. JUMAH M, Rahman F, Figgie M, Prasad A, et al
    COVID-19, HHV6 and MOG antibody: A perfect storm.
    J Neuroimmunol. 2021;353:577521.
    PubMed     Abstract available


  65. WANG J, Qiu Z, Li D, Dong H, et al
    Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
    J Neuroimmunol. 2021;353:577515.
    PubMed     Abstract available


  66. ZHANG H, Yang Y, Luo X
    Anti-MOG antibodies associated demyelination following encephalomeningitis: Case report.
    J Neuroimmunol. 2021;353:577519.
    PubMed     Abstract available


  67. LI C, Wang J, Sun X, Li R, et al
    The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.
    J Neuroimmunol. 2021;353:577506.
    PubMed     Abstract available


  68. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available


  69. FANG F, Wang Y, Xu W
    Anti-N-methyl-d-aspartate receptor encephalitis associated with intracranial cryptococcal infection: A case report and 2-year follow-up.
    J Neuroimmunol. 2021;353:577502.
    PubMed     Abstract available


  70. DU Q, Shi Z, Chen H, Zhang Y, et al
    Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2021;353:577494.
    PubMed     Abstract available


  71. PRADO MB JR, Narito KM, Adiao KJB
    Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever.
    J Neuroimmunol. 2021;355:577572.
    PubMed     Abstract available


  72. FAN Z, Zheng D, Wen X, Shen F, et al
    CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
    J Neuroimmunol. 2021;355:577571.
    PubMed     Abstract available


  73. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available


    March 2021
  74. GUEDES BF, Ribeiro AF, Pinto LF, Vidal JE, et al
    Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases.
    J Neuroimmunol. 2021;355:577548.
    PubMed     Abstract available


  75. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available


  76. DINOTO A, Bosco A, Sartori A, Bratina A, et al
    Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies.
    J Neuroimmunol. 2021;352:577488.
    PubMed     Abstract available


  77. LI X, Hou C, Wu WL, Liang H, et al
    Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: Analysis of 111 cases.
    J Neuroimmunol. 2021;352:577479.
    PubMed     Abstract available


  78. DAY GS, Gordon BA, Bucelli RC, Perrin RJ, et al
    Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.
    J Neuroimmunol. 2021;352:577474.
    PubMed     Abstract available


  79. COSSU D, Yokoyama K, Sakanishi T, Kuwahara-Arai K, et al
    A mucosal immune response induced by oral administration of heat-killed Mycobacterium avium subsp. paratuberculosis exacerbates EAE.
    J Neuroimmunol. 2021;352:577477.
    PubMed     Abstract available


  80. CHAUDHARY P, Marracci GH, Calkins E, Pocius E, et al
    Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
    J Neuroimmunol. 2021;352:577468.
    PubMed     Abstract available


  81. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed     Abstract available


    February 2021
  82. XIANG W, Xie C, Guan Y
    The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
    J Neuroimmunol. 2021;354:577520.
    PubMed     Abstract available


  83. LI H, Huang Z, Jia D, Xue H, et al
    Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    J Neuroimmunol. 2021;354:577528.
    PubMed     Abstract available


  84. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
    Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
    J Neuroimmunol. 2021;353:577525.
    PubMed     Abstract available


  85. AKAISHI T, Misu T, Takahashi T, Takai Y, et al
    Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
    J Neuroimmunol. 2021;351:577467.
    PubMed     Abstract available


  86. CHOUDHARY A, Bhargava A, Khichar S, Pradhan S, et al
    Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India.
    J Neuroimmunol. 2021;351:577456.
    PubMed     Abstract available


  87. THIRUNAVUKKARASU B, Gupta K, Nada R, Rathi M, et al
    Neuropathological spectrum in systemic lupus erythematosus: A single institute autopsy experience.
    J Neuroimmunol. 2021;353:577518.
    PubMed     Abstract available


  88. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
    Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
    J Neuroimmunol. 2021;353:577500.
    PubMed     Abstract available


  89. LI Q, Liu Y, Zeng Y
    Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577516.
    PubMed    


    January 2021
  90. YUE YX, Gao X, Tang TP, Xie Y, et al
    Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.
    J Neuroimmunol. 2021;353:577487.
    PubMed     Abstract available


  91. BEER R, Lehn A, Blum S
    A case of Anti-LGi-1 antibody positive autoimmune epilepsy following deep brain stimulator implantation for essential tremor.
    J Neuroimmunol. 2021;353:577503.
    PubMed     Abstract available


  92. NING P, Yang B, Yang X, Huang H, et al
    Lymphocyte-based ratios for predicting respiratory failure in Guillain-Barre syndrome.
    J Neuroimmunol. 2021;353:577504.
    PubMed     Abstract available


  93. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed     Abstract available


  94. BROADLEY J, Wesselingh R, Seneviratne U, Kyndt C, et al
    Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis.
    J Neuroimmunol. 2021;353:577508.
    PubMed     Abstract available


  95. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
    NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
    J Neuroimmunol. 2021;353:577499.
    PubMed     Abstract available


  96. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed     Abstract available


  97. NIU Y, Li Y
    The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
    J Neuroimmunol. 2021;352:577465.
    PubMed    


  98. MORIGUCHI K, Miyamoto K, Fukumoto Y, Kusunoki S, et al
    Change in light-dark cycle affects experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;353:577495.
    PubMed     Abstract available


  99. CHU Y, Jing Y, Zhao X, Wang M, et al
    Modulation of the HMGB1/TLR4/NF-kappaB signaling pathway in the CNS by matrine in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;352:577480.
    PubMed     Abstract available


  100. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
    Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
    J Neuroimmunol. 2021;352:577473.
    PubMed     Abstract available


    December 2020
  101. KOHLE F, Sprenger A, Klein I, Fink GR, et al
    Nerve conductions studies in experimental models of autoimmune neuritis: A meta-analysis and guideline.
    J Neuroimmunol. 2020;352:577470.
    PubMed     Abstract available


  102. STASCHEIT F, Li L, Mai K, Baum K, et al
    Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
    J Neuroimmunol. 2020;351:577469.
    PubMed     Abstract available


  103. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
    Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
    J Neuroimmunol. 2020;351:577466.
    PubMed     Abstract available


  104. AKAISHI T, Fujimori J, Takahashi T, Misu T, et al
    Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
    J Neuroimmunol. 2020;349:577431.
    PubMed     Abstract available


  105. UZAWA A, Ozawa Y, Yasuda M, Kuwabara S, et al
    Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
    J Neuroimmunol. 2020;349:577424.
    PubMed     Abstract available


  106. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
    A bibliometric evaluation of the top 100 cited natalizumab articles.
    J Neuroimmunol. 2020;349:577379.
    PubMed     Abstract available


  107. HUSSEIN O, Abd Elazim A, Torbey MT
    Covid-19 systemic infection exacerbates pre-existing acute disseminated encephalomyelitis (ADEM).
    J Neuroimmunol. 2020;349:577405.
    PubMed     Abstract available


  108. ZHENG Y, Luo J, Jin H, Gao F, et al
    Cerebrospinal fluid CD20 positive B-cell expansion in a case of anti-NMDAR encephalitis.
    J Neuroimmunol. 2020;349:577365.
    PubMed     Abstract available


    November 2020
  109. MOUTRAN-BARROSO H, Kreinter-Rosembaun H, Beltran S MA, Bayona H, et al
    The multiple faces of encephalitis: Antibody profile in a case series of autoimmune encephalitis in Bogota, Colombia.
    J Neuroimmunol. 2020;350:577451.
    PubMed     Abstract available


  110. MA X, Kermode AG, Hu X, Qiu W, et al
    NMOSD acute attack: Understanding, treatment and innovative treatment prospect.
    J Neuroimmunol. 2020;348:577387.
    PubMed     Abstract available


  111. GHOSH R, Dubey S, Ray BK, Purkait S, et al
    Isolated opsoclonus heralding neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2020;348:577394.
    PubMed     Abstract available


  112. XING X, Li J, Chen S, Zheng L, et al
    Anti-CASPR2 antibody associated encephalitis with anosmia and demyelinating pseudotumor: A case report.
    J Neuroimmunol. 2020;348:577393.
    PubMed     Abstract available


  113. KWON YN, Kim B, Ahn S, Seo J, et al
    Serum level of IL-1beta in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
    J Neuroimmunol. 2020;348:577361.
    PubMed     Abstract available


  114. GUO J, Han B, Wang J, Zhang L, et al
    The differential expression and potential roles of circular RNAs in children with anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2020;348:577381.
    PubMed     Abstract available


  115. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
    Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577432.
    PubMed     Abstract available


  116. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577433.
    PubMed     Abstract available


  117. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
    Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
    J Neuroimmunol. 2020;350:577435.
    PubMed     Abstract available


    October 2020
  118. SUN H, Wang J, Guo L, Wang Y, et al
    The combined treatment of NAD(+) and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.
    J Neuroimmunol. 2020;350:577429.
    PubMed     Abstract available


  119. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
    Modelling multiple sclerosis using induced pluripotent stem cells.
    J Neuroimmunol. 2020;349:577425.
    PubMed     Abstract available


  120. JEBALI A, Noroozi Karimabad M, Ahmadi Z, Khorramdel H, et al
    Attenuation of inflammatory response in the EAE model by PEGlated nanoliposome of pistachio oils.
    J Neuroimmunol. 2020;347:577352.
    PubMed     Abstract available


  121. QIU Y, Zhou Q, Du Q, Chen H, et al
    Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China.
    J Neuroimmunol. 2020;347:577351.
    PubMed    


  122. DUBEY S, Ghosh R, Dubey MJ, Sengupta S, et al
    Bilateral thalamic changes in anti-NMDAR encephalitis presenting with hemichorea and dystonia and acute transient psychotic disorder.
    J Neuroimmunol. 2020;347:577329.
    PubMed     Abstract available


  123. LI HX, Zuo L, Peng XX, Zong Q, et al
    Immunoglobulin G4-related hypertrophic pachymeningitis with spinal cord compression: A case report.
    J Neuroimmunol. 2020;347:577325.
    PubMed     Abstract available


    September 2020
  124. MATTEO G, Massimiliano T, Giorgia C, Silvia S, et al
    AQP4 autoantibodies in patients with idiopathic normal pressure hydrocephalus.
    J Neuroimmunol. 2020;349:577407.
    PubMed     Abstract available


  125. NEKRASOVA I, Shirshev S
    Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
    J Neuroimmunol. 2020;349:577421.
    PubMed     Abstract available


  126. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
    Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    J Neuroimmunol. 2020;349:577392.
    PubMed     Abstract available


  127. YAN C, Zhao R, Song J, Feng X, et al
    Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
    J Neuroimmunol. 2020;349:577403.
    PubMed     Abstract available


  128. YAMAKAWA M, Mukaino A, Kimura A, Nagasako Y, et al
    Antibodies to the alpha3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis.
    J Neuroimmunol. 2020;349:577399.
    PubMed     Abstract available


  129. YILMAZ V, Tuzun E, Durmus H, Oflazer P, et al
    The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients.
    J Neuroimmunol. 2020;349:577402.
    PubMed     Abstract available


  130. HOWLETT-PRIETO Q, Langer C, Rezania K, Soliven B, et al
    Modulation of immune responses by bile acid receptor agonists in myasthenia gravis.
    J Neuroimmunol. 2020;349:577397.
    PubMed     Abstract available


  131. ZHONG H, Lu J, Jing S, Xi J, et al
    Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
    J Neuroimmunol. 2020;348:577383.
    PubMed     Abstract available


  132. PARKHOUSE RME, Sciutto E, Hernandez M, Cortez MM, et al
    Extraparenchymal human neurocysticercosis induces autoantibodies against brain tubulin and MOG35-55 in cerebral spinal fluid.
    J Neuroimmunol. 2020;349:577389.
    PubMed     Abstract available


  133. DAS A, Khurshid S, Hayat S, Ahmed R, et al
    Glucocorticoid receptor gene polymorphisms in Guillain-Barre syndrome.
    J Neuroimmunol. 2020;348:577388.
    PubMed     Abstract available


  134. SIGNORIELLO E, Iardino P, Casertano S, De Lucia D, et al
    12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
    J Neuroimmunol. 2020;348:577385.
    PubMed     Abstract available


  135. ZOUVELOU V, Psimenou E
    AChR-and MuSK-positive myasthenia gravis: Double trouble.
    J Neuroimmunol. 2020;348:577364.
    PubMed     Abstract available


    August 2020
  136. ZHAN L, Fan M, Cai N, Cai B, et al
    Combination of autoimmune pancreatitis and peripheral neuropathy on an IgG4-related disease patient with 4 years following-up.
    J Neuroimmunol. 2020;348:577378.
    PubMed     Abstract available


  137. HEBERT J, Gros P, Lapointe S, Amtashar FS, et al
    Searching for autoimmune encephalitis: Beware of normal CSF.
    J Neuroimmunol. 2020;345:577285.
    PubMed     Abstract available


  138. LI X, Gao Q, Yang L, Han M, et al
    Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells.
    J Neuroimmunol. 2020;345:577286.
    PubMed     Abstract available


  139. JIAO L, Xiang Y, Li S, Zhang F, et al
    Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155.
    J Neuroimmunol. 2020;345:577280.
    PubMed     Abstract available


  140. ISMAIL S, Engin K, Ozan K, Mustafa C, et al
    Analysis of plasma protein biomarkers in childhood onset multiple sclerosis.
    J Neuroimmunol. 2020;348:577359.
    PubMed     Abstract available


  141. TRENOVA AG, Miteva LD, Stanilova SA
    Association between TNFA, IL10 and IL18 promoter gene variants and cognitive functions in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2020;347:577357.
    PubMed     Abstract available


  142. SOTIROPOULOS MG, Chitnis T
    Opposing and potentially antagonistic effects of BMP and TGF-beta in multiple sclerosis: The "Yin and Yang" of neuro-immune Signaling.
    J Neuroimmunol. 2020;347:577358.
    PubMed     Abstract available


  143. IBRAHIM SH, El-Mehdawy KM, Seleem M, El-Sawalhi MM, et al
    Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
    J Neuroimmunol. 2020;347:577356.
    PubMed     Abstract available


  144. SALAVISA M, Paixao P, Ladeira AF, Mendes A, et al
    Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse.
    J Neuroimmunol. 2020;347:577355.
    PubMed     Abstract available


    July 2020
  145. GARG D, Agarwal A, Bhagyawant R, Sikand TS, et al
    De novo nose-pinching stereotypy with somnolence: Clues to autoimmune encephalitis.
    J Neuroimmunol. 2020;347:577348.
    PubMed     Abstract available


  146. ACAR NP, Tuncer A, Ozkazanc D, Ozbay FG, et al
    An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta1 and fingolimod therapy.
    J Neuroimmunol. 2020;347:577353.
    PubMed     Abstract available


  147. GHADERIAN S, Shomali N, Behravesh S, Danbaran GR, et al
    The emerging role of lncRNAs in multiple sclerosis.
    J Neuroimmunol. 2020;347:577347.
    PubMed     Abstract available


  148. STEFANOVIC M, Zivotic I, Stojkovic L, Dincic E, et al
    The association of genetic variants IL2RA rs2104286, IFI30 rs11554159 and IKZF3 rs12946510 with multiple sclerosis onset and severity in patients from Serbia.
    J Neuroimmunol. 2020;347:577346.
    PubMed     Abstract available


  149. CULLER G, Bachman E, VanHaerents S
    Paraclinical serum markers as aids in the diagnosis of autoimmune encephalitis.
    J Neuroimmunol. 2020;347:577324.
    PubMed     Abstract available


  150. CIARDI MR, Zingaropoli MA, Pasculli P, Perri V, et al
    The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.
    J Neuroimmunol. 2020;346:577323.
    PubMed     Abstract available


  151. KENNEDY PGE, Graner MW, Walker D, Pointon T, et al
    Recombinant antibodies derived from laser captured single plasma cells of multiple sclerosis brain identified phage peptides which may be used as tools for characterizing intrathecal IgG response.
    J Neuroimmunol. 2020;347:577319.
    PubMed     Abstract available


  152. TIAN X, Chen C, Ma L, Wei R, et al
    Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2020;347:577317.
    PubMed     Abstract available


  153. HOUEN G, Heiden J, Trier NH, Draborg AH, et al
    Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis.
    J Neuroimmunol. 2020;346:577314.
    PubMed     Abstract available


  154. KEYVANI H, Zahednasab H, Aljanabi HAA, Asadi M, et al
    The role of human herpesvirus-6 and inflammatory markers in the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2020;346:577313.
    PubMed     Abstract available


    June 2020
  155. YETKIN MF, Mirza M
    Neutrophil to-lymphocyte ratio as a possible predictor of prognosis in recently diagnosed multiple sclerosis patients.
    J Neuroimmunol. 2020;346:577307.
    PubMed    


  156. FARAHMAND F, Nourshahi M, Soleimani M, Rajabi H, et al
    The effect of 6 weeks of high intensity interval training on myelin biomarkers and demyelination in experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2020;346:577306.
    PubMed     Abstract available


  157. FARZI MA, Ayromlou H, Jahanbakhsh N, Bavil PH, et al
    Guillain-Barre syndrome in a patient infected with SARS-CoV-2, a case report.
    J Neuroimmunol. 2020;346:577294.
    PubMed     Abstract available


  158. AL-NASERI MAS, Salman ED, Ad'hiah AH
    Relapsing-remitting multiple sclerosis: A profile of interleukine-1 gene cluster polymorphisms in Iraqi patients.
    J Neuroimmunol. 2020;346:577291.
    PubMed     Abstract available


  159. RYBERG B, Arvidsson A, Bergkvist M, Nilsson P, et al
    Limbic encephalitis in a neuroscientist: CASPR 2 antibody-associated disease after antigen exposure.
    J Neuroimmunol. 2020;343:577231.
    PubMed     Abstract available


  160. JUNG KO, Moon HJ
    A case of NMDAR encephalitis treated in the third trimester - novel arterial spin labeling findings and a review of literature.
    J Neuroimmunol. 2020;343:577235.
    PubMed     Abstract available


  161. AKAISHI T, Takahashi T, Fujihara K, Misu T, et al
    Risk factors of attacks in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;343:577236.
    PubMed     Abstract available


  162. GONZALEZ-ALVARADO MN, Rotger C, Berger L, London B, et al
    Functional role of endogenous Kv1.4 in experimental demyelination.
    J Neuroimmunol. 2020;343:577227.
    PubMed     Abstract available


  163. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
    Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    J Neuroimmunol. 2020;343:577230.
    PubMed     Abstract available


  164. SUN H, Ma X, Sun X, Wu L, et al
    Is transient hyperCKemia a new feature of neuromyelitis optica spectrum disorders? A retrospective study in 439 patients.
    J Neuroimmunol. 2020;343:577228.
    PubMed     Abstract available


  165. AHARONI R, Eilam R, Schottlender N, Radomir L, et al
    Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis.
    J Neuroimmunol. 2020;345:577281.
    PubMed     Abstract available


    May 2020
  166. RACKE MK, Newsome SD
    Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
    J Neuroimmunol. 2020 May 31:577283. doi: 10.1016/j.jneuroim.2020.577283.
    PubMed    


  167. CHIARINI M, Paghera S, Moratto D, Rossi N, et al
    Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    J Neuroimmunol. 2020;345:577282.
    PubMed     Abstract available


  168. LI Y, Guptill JT, Russo MA, Howard JF Jr, et al
    Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis.
    J Neuroimmunol. 2020;345:577279.
    PubMed     Abstract available


  169. GRIFFITH SP, Malpas CB, Alpitsis R, O'Brien TJ, et al
    The neuropsychological spectrum of anti-LGI1 antibody mediated autoimmune encephalitis.
    J Neuroimmunol. 2020;345:577271.
    PubMed     Abstract available


  170. MAURICE C, Khoja L, Morgan E, Mason WP, et al
    Guillain-Barre Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming.
    J Neuroimmunol. 2020;346:577267.
    PubMed     Abstract available


  171. KAPADIA RK, Ney DE, Hannan M, Farley M, et al
    Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
    J Neuroimmunol. 2020;344:577259.
    PubMed     Abstract available


    April 2020
  172. KEFALOPOULOU ZM, Liossis SN, Sagona T, Veltsista D, et al
    An ischemic stroke as the presenting manifestation of rapidly progressive primary angiitis of central nervous system in a 17-year-old boy.
    J Neuroimmunol. 2020;341:577190.
    PubMed     Abstract available


  173. LI X, Guo Q, Zheng Z, Wang X, et al
    Immune-mediated epilepsy with GAD65 antibodies.
    J Neuroimmunol. 2020;341:577189.
    PubMed     Abstract available


  174. BERNARDO F, Rebordao L, Rego A, Machado S, et al
    Stiff person spectrum disorders: An illustrative case series of their phenotypic and antibody diversity.
    J Neuroimmunol. 2020;341:577192.
    PubMed     Abstract available


  175. SHIBUYA K, Tsuneyama A, Misawa S, Sekiguchi Y, et al
    Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes.
    J Neuroimmunol. 2020;341:577170.
    PubMed     Abstract available


  176. PREVEZIANOU A, Tzartos JS, Dagklis IE, Bentenidi E, et al
    Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
    J Neuroimmunol. 2020;344:577242.
    PubMed     Abstract available


  177. ANEJA J, Kuppili PP, Paul K, Panda S, et al
    Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male.
    J Neuroimmunol. 2020;343:577238.
    PubMed     Abstract available


  178. BOULLERNE AI, Adami GR, Schwartz JL, Skias D, et al
    Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity.
    J Neuroimmunol. 2020;343:577237.
    PubMed     Abstract available


  179. PARKHOUSE RME, Carpio A, Cortez MM, von Kriegsheim A, et al
    Anti-brain protein autoantibodies are detectable in extraparenchymal but not parenchymal neurocysticercosis.
    J Neuroimmunol. 2020;344:577234.
    PubMed     Abstract available


    March 2020
  180. PRABHAT N, Chakravarty K, Pattnaik SN, Takkar A, et al
    Systemic lupus erythematosus with autoimmune neurological manifestations in a carrier of chronic granulomatous disease - a rare presentation.
    J Neuroimmunol. 2020;343:577229.
    PubMed     Abstract available


  181. MUKE I, Sprenger A, Bobylev I, Wiemer V, et al
    Ultrastructural characterization of mitochondrial damage in experimental autoimmune neuritis.
    J Neuroimmunol. 2020;343:577218.
    PubMed     Abstract available


  182. BOLDRINI VO, Brandao CO, Pimentel MLV, Vidal A, et al
    Massive activity of cytotoxic cells during refractory Neuromyelitis Optica spectrum disorder.
    J Neuroimmunol. 2020;340:577148.
    PubMed     Abstract available


  183. AKAISHI T, Takahashi T, Himori N, Fujihara K, et al
    Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;340:577168.
    PubMed     Abstract available


  184. URIBE-SAN-MARTIN R, Ciampi E, Cruz JP, Vasquez M, et al
    Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate.
    J Neuroimmunol. 2020;340:577144.
    PubMed     Abstract available


  185. MADDISON P, Gozzard P, Sadalage G, Ambrose PA, et al
    Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
    J Neuroimmunol. 2020;340:577149.
    PubMed     Abstract available


  186. PEDAPATI R, Bhatia R, Singh N, Bali P, et al
    Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - A north Indian tertiary care centre experience and review of literature.
    J Neuroimmunol. 2020;340:577143.
    PubMed     Abstract available


  187. MACCHI ZA, Kleinschmidt-DeMasters BK, Orjuela KD, Pastula DM, et al
    Glioblastoma as an autoimmune limbic encephalitis mimic: A case and review of the literature.
    J Neuroimmunol. 2020;342:577214.
    PubMed     Abstract available


  188. PETKOVIC F, Lazzarino GP, Engblom D, Blomqvist A, et al
    IL-6R expressed on CNS vascular endothelial cells contributes to the development of experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2020;342:577211.
    PubMed     Abstract available


  189. TAHMASEBIVAND M, Mousavi SR, Khorrami M, Ayromlou H, et al
    miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta.
    J Neuroimmunol. 2020;342:577212.
    PubMed     Abstract available


  190. MCGILL MM, Sabikunnahar B, Fang Q, Teuscher C, et al
    The sex-specific role of p38 MAP kinase in CNS autoimmunity is regulated by estrogen receptor alpha.
    J Neuroimmunol. 2020;342:577209.
    PubMed    


    February 2020
  191. PEREZ CA, Shah EG, Butler IJ
    Mercury-induced autoimmunity: Report of two adolescent siblings with Morvan syndrome "plus" and review of the literature.
    J Neuroimmunol. 2020;342:577197.
    PubMed     Abstract available


  192. LISAK RP, Nedelkoska L, Benjamins JA
    Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis.
    J Neuroimmunol. 2020;342:577188.
    PubMed     Abstract available


  193. OGATA H, Isobe N, Zhang X, Yamasaki R, et al
    Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2020;339:577139.
    PubMed     Abstract available


  194. SHI Z, Qiu Y, Wang J, Fang Y, et al
    Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.
    J Neuroimmunol. 2020;339:577126.
    PubMed     Abstract available


  195. BRILL L, Vaknin-Dembinsky A, Zveik O, Haham N, et al
    MIF -173G/C polymorphism is associated with NMO disease severity.
    J Neuroimmunol. 2020;339:577120.
    PubMed     Abstract available


  196. GARIMELLA V, McVoy JS, Oh U
    The contribution of cyclophilin A to immune-mediated central nervous system inflammation.
    J Neuroimmunol. 2020;339:577118.
    PubMed     Abstract available


  197. ZHANG W, Dong M, Dong H, Wang W, et al
    Reduced sarcolemmal aquaporin 4 expression can support the differential diagnosis of neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;339:577121.
    PubMed     Abstract available


  198. GOMES NA, Silva PC, Teixeira YT, Eufrazio P, et al
    HLA-G Ins/Del polymorphism and +3142C/G SNP are not related to neuromyelitis optica spectrum disorder (NMOSD) development, disability status or anti-aquaporin 4 presence in Brazilian patients.
    J Neuroimmunol. 2020;339:577112.
    PubMed     Abstract available


  199. NYSTAD AE, Lereim RR, Wergeland S, Oveland E, et al
    Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
    J Neuroimmunol. 2020;339:577091.
    PubMed     Abstract available


  200. HABIB R, Ocklenburg S, Hoffjan S, Haghikia A, et al
    Association between shorter leukocyte telomeres and multiple sclerosis.
    J Neuroimmunol. 2020;341:577187.
    PubMed     Abstract available


  201. TRAN GT, Hodgkinson SJ, Carter N, Verma ND, et al
    Autoantigen specific IL-2 activated CD4(+)CD25(+)T regulatory cells inhibit induction of experimental autoimmune neuritis.
    J Neuroimmunol. 2020;341:577186.
    PubMed     Abstract available


    January 2020
  202. SHAHIDI SH, Kordi MR, Rajabi H, Malm C, et al
    Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis.
    J Neuroimmunol. 2020;341:577172.
    PubMed     Abstract available


  203. HEMING M, Lohmann L, Schulte-Mecklenbeck A, Brix T, et al
    Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.
    J Neuroimmunol. 2020;341:577171.
    PubMed     Abstract available


  204. SAHAMI-FARD MH, Mozhdeh M, Izadpanah F, Kashani HH, et al
    Interleukin 7 receptor T244I polymorphism and the multiple sclerosis susceptibility: a meta-analysis.
    J Neuroimmunol. 2020;341:577166.
    PubMed     Abstract available


  205. LIU S, Zhang X, Wang J, Yang H, et al
    Analysis of plasma autoantibodies for inflammatory cytokines in patients with first-episode schizophrenia among a Chinese population.
    J Neuroimmunol. 2020;341:577165.
    PubMed     Abstract available


  206. ZHANG Y, Zhang Q, Shi Z, Chen H, et al
    Sexual dysfunction in patients with neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2020;338:577093.
    PubMed     Abstract available


  207. AGASING AM, Gawde S, Kumar G, Turner E, et al
    B cell function impacts the efficacy of IFN-beta therapy in EAE.
    J Neuroimmunol. 2020;338:577106.
    PubMed     Abstract available


  208. BLACKBURN K, Wang C, Greenberg B
    Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma.
    J Neuroimmunol. 2020;338:577092.
    PubMed     Abstract available


  209. DAS NEVES SP, Santos G, Barros C, Pereira DR, et al
    Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms.
    J Neuroimmunol. 2020;340:577163.
    PubMed     Abstract available


  210. PANDYA D, Hellerslia V, Gettings E
    Acquired factor VIII inhibitor in a patient with multiple sclerosis treated with interferon beta-1a.
    J Neuroimmunol. 2020;340:577146.
    PubMed     Abstract available


  211. HAKANSSON I, Ernerudh J, Vrethem M, Dahle C, et al
    Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2020;340:577147.
    PubMed     Abstract available


    December 2019
  212. NOVIKOVA NS, Diatlova AS, Derevtsova KZ, Korneva EA, et al
    Corrigendum to "Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis" [J Neuroimmunol. 2019 Dec 15;337:577070. doi: 10.1016/j.jneuroim.2019.577070. Epub 2019 Oct 24].
    J Neuroimmunol. 2019 Dec 27:577137. doi: 10.1016/j.jneuroim.2019.577137.
    PubMed    


  213. JOOB B, Wiwanitkit V
    Tumor necrosis factor alpha -863C/A polymorphism and Guillain-Barre Syndrome.
    J Neuroimmunol. 2019;339:577140.
    PubMed    


  214. LAZARIDIS K, Baltatzidou V, Tektonidis N, Tzartos SJ, et al
    Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of MuSK-induced experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2019;339:577136.
    PubMed     Abstract available


  215. SHIMASAKI C, Frye RE, Trifiletti R, Cooperstock M, et al
    Evaluation of the Cunningham Panel in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes
    J Neuroimmunol. 2019;339:577138.
    PubMed     Abstract available


  216. UZAWA A, Ozawa Y, Yasuda M, Oda F, et al
    Increased serum acetylcholine receptor alpha1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis.
    J Neuroimmunol. 2019;339:577125.
    PubMed     Abstract available


  217. PEREZ CA, Agyei P, Gogia B, Harrison R, et al
    Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease.
    J Neuroimmunol. 2019;339:577124.
    PubMed     Abstract available


  218. CAVALLA P, Caropreso P, Limoncelli S, Bosa C, et al
    Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders.
    J Neuroimmunol. 2019;339:577122.
    PubMed     Abstract available


    November 2019
  219. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    J Neuroimmunol. 2019;339:577113.
    PubMed     Abstract available


  220. MARCUCCI SB, Obeidat AZ
    EBNA1, EBNA2, and EBNA3 link Epstein-Barr virus and hypovitaminosis D in multiple sclerosis pathogenesis.
    J Neuroimmunol. 2019;339:577116.
    PubMed     Abstract available


  221. GLENN JD, Pantoja IM, Caturegli P, Whartenby KA, et al
    MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;339:577115.
    PubMed     Abstract available


  222. AMMITZBOLL C, von Essen MR, Chow HH, McWilliam O, et al
    MAIT cell subtypes in multiple sclerosis.
    J Neuroimmunol. 2019;339:577117.
    PubMed     Abstract available


  223. SPANIER JA, Nashold FE, Nelson CD, Praska CE, et al
    Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4(+) T cell CTLA-4 expression.
    J Neuroimmunol. 2019;338:577105.
    PubMed     Abstract available


  224. NASI M, Bianchini E, De Biasi S, Gibellini L, et al
    Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2019;338:577107.
    PubMed     Abstract available


  225. GAETANI L, Di Carlo M, Brachelente G, Valletta F, et al
    Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis.
    J Neuroimmunol. 2019;339:577108.
    PubMed     Abstract available


  226. ARRU G, Sechi E, Mariotto S, Zarbo IR, et al
    Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD.
    J Neuroimmunol. 2019;338:577110.
    PubMed     Abstract available


    October 2019
  227. CAO Q, Zheng C, Xie Z, Liu L, et al
    The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3.
    J Neuroimmunol. 2019;338:577079.
    PubMed     Abstract available


  228. KOLIC I, Stojkovic L, Dincic E, Jovanovic I, et al
    Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;338:577090.
    PubMed     Abstract available


  229. NOVIKOVA NS, Diatlova AS, Derevtsova KZ, Korneva EA, et al
    Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;337:577070.
    PubMed     Abstract available


  230. HAN J, Zhang J, Li M, Zhang Y, et al
    A novel MuSK cell-based myasthenia gravis diagnostic assay.
    J Neuroimmunol. 2019;337:577076.
    PubMed     Abstract available


  231. BASNYAT P, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis.
    J Neuroimmunol. 2019;335:577020.
    PubMed     Abstract available


  232. SOUTO EB, Lima B, Campos JR, Martins-Gomes C, et al
    Myasthenia gravis: State of the art and new therapeutic strategies.
    J Neuroimmunol. 2019;337:577080.
    PubMed     Abstract available


  233. KAMMEYER R, Piquet AL
    Multiple co-existing antibodies in autoimmune encephalitis: A case and review of the literature.
    J Neuroimmunol. 2019;337:577084.
    PubMed     Abstract available


  234. PETERSEN ER, Ammitzboll C, Sondergaard HB, Oturai AB, et al
    Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis.
    J Neuroimmunol. 2019;337:577085.
    PubMed     Abstract available


    September 2019
  235. RANJBAR R, Karampoor S, Jalilian FA
    The protective effect of Helicobacter Pylori infection on the susceptibility of multiple sclerosis.
    J Neuroimmunol. 2019;337:577069.
    PubMed     Abstract available


  236. BOYAO Y, Mengjiao S, Caicai B, Xiaoling L, et al
    Dynamic expression of autophagy-related factors in autoimmune encephalomyelitis and exploration of curcumin therapy.
    J Neuroimmunol. 2019;337:577067.
    PubMed     Abstract available


  237. KURTUNCU M, Yilmaz V, Akcay HI, Turkoglu R, et al
    Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2019;337:577065.
    PubMed     Abstract available


  238. CARLOS CE, Gianfranco CS, Miguel CC, Crist EA, et al
    Is there a significant association between tumor necrosis factor alpha -863C/A polymorphism and the development of Guillain-Barre Syndrome?
    J Neuroimmunol. 2019;337:577064.
    PubMed    


  239. ABDEL-DAYEM MA, Shaker ME, Gameil NM
    Impact of interferon beta-1b, interferon beta-1a and fingolimod therapies on serum interleukins-22, 32alpha and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577062.
    PubMed     Abstract available


  240. AFSHAR B, Khalifehzadeh-Esfahani Z, Seyfizadeh N, Rezaei Danbaran G, et al
    The role of immune regulatory molecules in multiple sclerosis.
    J Neuroimmunol. 2019;337:577061.
    PubMed     Abstract available


  241. MARGONI M, Carotenuto A
    Very late-onset recurrent myelitis in a patient diagnosed with antiphospholipid syndrome: A puzzle of autoimmunity.
    J Neuroimmunol. 2019;337:577051.
    PubMed     Abstract available


  242. BROOKS PT, Bell JA, Bejcek CE, Malik A, et al
    An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model.
    J Neuroimmunol. 2019;337:577048.
    PubMed     Abstract available


    August 2019
  243. LIANG H, Gao W, Liu X, Liu J, et al
    The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population.
    J Neuroimmunol. 2019;337:577045.
    PubMed     Abstract available


  244. ZAROBKIEWICZ MK, Kowalska W, Halczuk P, Wos J, et al
    RORgammaT is overexpressed in iNKT and gammadelta T cells during relapse in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577046.
    PubMed     Abstract available


  245. ZHANG G, Wang Q, Song Y, Cheng P, et al
    Intravenous immunoglobulin promotes the proliferation of CD4(+)CD25(+) Foxp3(+) regulatory T cells and the cytokines secretion in patients with Guillain-Barre syndrome in vitro.
    J Neuroimmunol. 2019;336:577042.
    PubMed     Abstract available


  246. SVEINSSON O, Piehl F, Aspegren O, Hietala MA, et al
    Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome.
    J Neuroimmunol. 2019;336:577028.
    PubMed     Abstract available


  247. DURCAN R, Heffron C, Sweeney B
    Natalizumab induced cutaneous sarcoidosis-like reaction.
    J Neuroimmunol. 2019;333:476955.
    PubMed     Abstract available


  248. KAUSHANSKY N, Kaminitz A, Allouche-Arnon H, Ben-Nun A, et al
    Modulation of MS-like disease by a multi epitope protein is mediated by induction of CD11c(+)CD11b(+)Gr1(+) myeloid-derived dendritic cells.
    J Neuroimmunol. 2019;333:476953.
    PubMed     Abstract available


    July 2019
  249. NAKAMURA Y, Igaki K, Uga K, Shibata A, et al
    Pharmacological evaluation of TAK-828F, a novel orally available RORgammat inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2019;335:577016.
    PubMed     Abstract available


  250. NOSADINI M, Toldo I, Tascini B, Bien CG, et al
    LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome.
    J Neuroimmunol. 2019;335:577008.
    PubMed     Abstract available


  251. DEL FABBRO L, de Gomes MG, Souza LC, Goes AR, et al
    Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2019;335:577007.
    PubMed     Abstract available


  252. NICOLETTI F, Mazzon E, Fagone P, Mangano K, et al
    Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF.
    J Neuroimmunol. 2019;332:224-232.
    PubMed     Abstract available


  253. DZANGUE-TCHOUPOU G, Allenbach Y, Preusse C, Stenzel W, et al
    Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome.
    J Neuroimmunol. 2019;332:212-215.
    PubMed     Abstract available


  254. JAZEBI N, Rodrigo S, Gogia B, Shawagfeh A, et al
    Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
    J Neuroimmunol. 2019;332:135-137.
    PubMed     Abstract available


  255. ENRIQUEZ CAG, Espiritu AI, Pasco PMD
    Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
    J Neuroimmunol. 2019;332:126-134.
    PubMed     Abstract available


  256. NEEDHAM EJ, Helmy A, Zanier ER, Jones JL, et al
    The immunological response to traumatic brain injury.
    J Neuroimmunol. 2019;332:112-125.
    PubMed     Abstract available


  257. FREUND B, Ritzl EK
    A review of EEG in anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2019;332:64-68.
    PubMed     Abstract available


  258. CAVALIERE E, Nosadini M, Pelizza MF, Ventura G, et al
    Anti-NMDAR encephalitis preceded by non-herpetic central nervous system infection: Systematic literature review and first case of tick-borne encephalitis triggering anti-NMDAR encephalitis.
    J Neuroimmunol. 2019;332:1-7.
    PubMed     Abstract available


    June 2019
  259. KIMURA A, Takemura M, Yamamoto Y, Hayashi Y, et al
    Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications.
    J Neuroimmunol. 2019;334:576999.
    PubMed     Abstract available


  260. NICKEL M, Eid F, Jukkola P, Gu C, et al
    Copper chelation and autoimmunity differentially impact myelin in the hippocampal-prefrontal circuit.
    J Neuroimmunol. 2019;334:576998.
    PubMed     Abstract available


  261. LAMPORT AC, Chedrawe M, Nichols M, Robertson GS, et al
    Experimental autoimmune encephalomyelitis accelerates remyelination after lysophosphatidylcholine-induced demyelination in the corpus callosum.
    J Neuroimmunol. 2019;334:576995.
    PubMed     Abstract available


  262. IMITOLA J
    Regenerative neuroimmunology: The impact of immune and neural stem cell interactions for translation in neurodegeneration and repair.
    J Neuroimmunol. 2019;331:1-3.
    PubMed    


  263. ANTEL JP, Lin YH, Cui QL, Pernin F, et al
    Immunology of oligodendrocyte precursor cells in vivo and in vitro.
    J Neuroimmunol. 2019;331:28-35.
    PubMed     Abstract available


  264. ZORLU N, Hoffjan S, Haghikia A, Deyneko IV, et al
    Evaluation of variation in genes of the arylhydrocarbon receptor pathway for an association with multiple sclerosis.
    J Neuroimmunol. 2019;334:576979.
    PubMed     Abstract available


    May 2019
  265. KOCH MW, Liu WQ, Camara-Lemarroy C, Zhang Y, et al
    Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.
    J Neuroimmunol. 2019;334:576974.
    PubMed     Abstract available


  266. ZURAWSKA A, Mycko MP, Selmaj KW
    Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis.
    J Neuroimmunol. 2019;334:576971.
    PubMed     Abstract available


  267. RASOOLI TEHRANI A, Gholipour S, Sharifi R, Yadegari S, et al
    Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.
    J Neuroimmunol. 2019;333:576968.
    PubMed     Abstract available


  268. TOMESCU-BACIU A, Johansen JN, Holmoy T, Greiff V, et al
    Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis.
    J Neuroimmunol. 2019;333:576966.
    PubMed     Abstract available


  269. SHOU J, Peng J, Zhao Z, Huang X, et al
    CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;333:576967.
    PubMed     Abstract available


  270. XU H, Zhang M, Li XL, Li H, et al
    Corrigendum to: "low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways" [Journal of Neuroimmunology 281 (2015) 61-67].
    J Neuroimmunol. 2019;330:181-183.
    PubMed    


  271. QU Z, Zheng N, Wei Y, Chen Y, et al
    Effect of cornel iridoid glycoside on microglia activation through suppression of the JAK/STAT signalling pathway.
    J Neuroimmunol. 2019;330:96-107.
    PubMed     Abstract available


  272. SHOUMAN K, Prieto PG, Stino AM, Lisak RP, et al
    Serum Creatine Kinase in Patients with Neuromyelitis Optica Spectrum Disorder.
    J Neuroimmunol. 2019;330:87-89.
    PubMed     Abstract available


  273. DENG B, Yu H, Liu X, Yu X, et al
    Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients.
    J Neuroimmunol. 2019;330:81-86.
    PubMed     Abstract available


  274. KELLER CW, Quast I, Dalakas MC, Lunemann JD, et al
    IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.
    J Neuroimmunol. 2019;330:23-27.
    PubMed     Abstract available


  275. KAMO H, Ueno Y, Sugiyama M, Miyamoto N, et al
    Pontine hemorrhage accompanied by neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2019;330:19-22.
    PubMed     Abstract available


  276. MONTEIRO C, Fernandes G, Kasahara TM, Barros PO, et al
    The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2019;330:12-18.
    PubMed     Abstract available


  277. SPENCE S, Ng D, Casault C
    Atypical presentation of fulminant primary central nervous system angiitis.
    J Neuroimmunol. 2019;330:1-4.
    PubMed     Abstract available


  278. BRIANI C, Salvalaggio A, Ruiz M, Cacciavillani M, et al
    Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy.
    J Neuroimmunol. 2019;330:178-180.
    PubMed     Abstract available


  279. YOON L, Kim BR, Kim HY, Kwak MJ, et al
    Clinical characterization of anti-GQ1b antibody syndrome in Korean children.
    J Neuroimmunol. 2019;330:170-173.
    PubMed     Abstract available


  280. JING S, Lu J, Song J, Luo S, et al
    Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis.
    J Neuroimmunol. 2019;332:216-223.
    PubMed     Abstract available


  281. LOVETT-RACKE AE, Gormley M, Liu Y, Yang Y, et al
    B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
    J Neuroimmunol. 2019;332:187-197.
    PubMed     Abstract available


  282. BORHANI-HAGHIGHI M, Mohamadi Y
    The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2019;333:476958.
    PubMed     Abstract available


    April 2019
  283. SETIADI AF, Abbas AR, Jeet S, Wong K, et al
    IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;332:147-154.
    PubMed     Abstract available


  284. KIRA JI, Isobe N
    Helicobacter pylori infection and demyelinating disease of the central nervous system.
    J Neuroimmunol. 2019;329:14-19.
    PubMed     Abstract available


  285. KIMURA A, Takekoshi A, Yoshikura N, Hayashi Y, et al
    Clinical characteristics of autoimmune GFAP astrocytopathy.
    J Neuroimmunol. 2019;332:91-98.
    PubMed     Abstract available


  286. MADDISON P, Sadalage G, Ambrose PA, Jacob S, et al
    False-positive acetylcholine receptor antibody results in patients without myasthenia gravis.
    J Neuroimmunol. 2019;332:69-72.
    PubMed     Abstract available


  287. SUN Y, Jing Y, Huang M, Ma J, et al
    The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides.
    J Neuroimmunol. 2019;332:78-90.
    PubMed     Abstract available


    March 2019
  288. SCHLIFFKE S, Carambia A, Akyuz N, Thiele B, et al
    T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model.
    J Neuroimmunol. 2019;332:49-56.
    PubMed     Abstract available


  289. VAITAITIS GM, Yussman MG, Wagner DH Jr
    A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;332:8-15.
    PubMed     Abstract available


  290. ROJC B, Podnar B, Graus F
    A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: Different biological evolution of the two associated antibodies.
    J Neuroimmunol. 2019;328:86-88.
    PubMed     Abstract available


  291. GARG M, Mittal J, Gupta P
    Association of typhoid fever with anti-NMDAR encephalitis in a young child.
    J Neuroimmunol. 2019;328:76-77.
    PubMed    


  292. GASTALDI M, Arbasino C, Dallocchio C, Diamanti L, et al
    NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease.
    J Neuroimmunol. 2019;328:35-37.
    PubMed     Abstract available


  293. VOO VTF, O'Brien T, Butzkueven H, Monif M, et al
    The role of vitamin D and P2X7R in multiple sclerosis.
    J Neuroimmunol. 2019;330:159-169.
    PubMed     Abstract available


  294. HILLIS JM, Mateen FJ
    Neuromyelitis optica after splenectomy: A secondary autoimmune phenomenon.
    J Neuroimmunol. 2019;330:152-154.
    PubMed     Abstract available


  295. CIERNY D, Michalik J, Dubovan P, Skerenova M, et al
    The association of rs703842 variants in CYP27B1 with multiple sclerosis susceptibility is influenced by the HLA-DRB1*15:01 allele in Slovaks.
    J Neuroimmunol. 2019;330:123-129.
    PubMed     Abstract available


  296. ANNUNZIATA P, Masi G, Cioni C
    Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.
    J Neuroimmunol. 2019;330:130-135.
    PubMed     Abstract available


  297. AMMITZBOLL C, Bornsen L, Petersen ER, Oturai AB, et al
    Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.
    J Neuroimmunol. 2019;330:90-95.
    PubMed     Abstract available


    February 2019
  298. ZHANG DQ, Deng Y, Zhang LJ, Li LM, et al
    Elevated resistin levels may regulate high mobility group box 1 expression in Guillain-Barre syndrome.
    J Neuroimmunol. 2019;330:59-66.
    PubMed     Abstract available


  299. DA SILVA BERNARDES M, Antao Paiva CL, Ribeiro Paradela E, Papais Alvarenga M, et al
    Familial multiple sclerosis in a Brazilian sample: Is HLA-DR15 involved in susceptibility to the disease?
    J Neuroimmunol. 2019;330:74-80.
    PubMed     Abstract available


  300. ZAROBKIEWICZ MK, Kowalska W, Rolinski J, Bojarska-Junak AA, et al
    gammadelta T lymphocytes in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;330:67-73.
    PubMed     Abstract available


  301. AL-TEMAIMI R, Cherian P, Abu-Farha M, Alroughani R, et al
    Angiopoietin-like proteins in multiple sclerosis.
    J Neuroimmunol. 2019;330:31-34.
    PubMed     Abstract available


  302. GILLINDER L, Papacostas J, Dionisio S
    Electroclinical insights into autoimmune epilepsy.
    J Neuroimmunol. 2019;330:44-47.
    PubMed     Abstract available


  303. SAVAGE SA, Irani SR, Leite MI, Zeman AZ, et al
    NMDA receptor antibody encephalitis presenting as Transient Epileptic Amnesia.
    J Neuroimmunol. 2019;327:41-43.
    PubMed     Abstract available


    January 2019
  304. COSSU D, Yokoyama K, Sakanishi T, Momotani E, et al
    Adjuvant and antigenic properties of Mycobacterium avium subsp. paratuberculosis on experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019 Jan 23. pii: S0165-5728(18)30552.
    PubMed     Abstract available


  305. JAYASIMHAN A, Ellis DP, Ziegler AI, Slattery RM, et al
    Pancreatic ductal cell antigens are important in the development of invasive insulitis in Non-Obese Diabetic mice.
    J Neuroimmunol. 2019 Jan 18. pii: S0165-5728(18)30263.
    PubMed     Abstract available


  306. MAUSNER-FAINBERG K, Penn M, Golan M, Benhamou M, et al
    Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30476.
    PubMed     Abstract available


  307. DOLATI S, Babaloo Z, Ayromlou H, Ahmadi M, et al
    Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30466.
    PubMed     Abstract available


  308. KOHLER S, Keil T, Alexander T, Thiel A, et al
    Altered naive CD4(+) T cell homeostasis in myasthenia gravis and thymoma patients.
    J Neuroimmunol. 2019 Jan 11. pii: S0165-5728(18)30380.
    PubMed     Abstract available


    December 2018
  309. EMAMI ALEAGHA MS, Siroos B, Allameh A, Shakiba S, et al
    Calcitriol, but not FGF23, increases in CSF and serum of MS patients.
    J Neuroimmunol. 2018;328:89-93.
    PubMed     Abstract available


  310. DEMIR S, Pitarokoili K, Linker R, Gold R, et al
    Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
    J Neuroimmunol. 2018;328:78-85.
    PubMed     Abstract available


  311. ARAMIDEH KHOUY R, Karampoor S, Keyvani H, Bokharaei-Salim F, et al
    The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    J Neuroimmunol. 2018;328:94-97.
    PubMed     Abstract available


  312. XIE Y, Li Z, Wang Y, Xue X, et al
    Effects of moderate- versus high- intensity swimming training on inflammatory and CD4(+) T cell subset profiles in experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2018;328:60-67.
    PubMed     Abstract available


  313. MEHTA D, Wani S, Wallace L, Henders AK, et al
    Cumulative influence of parity-related genomic changes in multiple sclerosis.
    J Neuroimmunol. 2018;328:38-49.
    PubMed     Abstract available


  314. YOUSEFI F, Lavi Arab F, Saeidi K, Amiri H, et al
    Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection.
    J Neuroimmunol. 2018;328:20-34.
    PubMed     Abstract available


    November 2018
  315. LEE EJ, Lim YM, Kim SY, Lee J, et al
    The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2018;328:1-4.
    PubMed     Abstract available


  316. MASOUMI F, Ghorbani S, Talebi F, Branton WG, et al
    Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;328:50-59.
    PubMed     Abstract available


  317. MONTEIRO A, Cruto C, Rosado P, Rosado L, et al
    Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts.
    J Neuroimmunol. 2018;326:49-54.
    PubMed     Abstract available


  318. ANNIBALI V, Umeton R, Palermo A, Severa M, et al
    Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients.
    J Neuroimmunol. 2018;324:165-171.
    PubMed     Abstract available


  319. LOTAN I, Hellmann MA, Benninger F, Stiebel-Kalish H, et al
    Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.
    J Neuroimmunol. 2018;324:115-118.
    PubMed     Abstract available


  320. MOORE JR, Hubler SL, Nelson CD, Nashold FE, et al
    1,25-Dihydroxyvitamin D3 increases the methionine cycle, CD4(+) T cell DNA methylation and Helios(+)Foxp3(+) T regulatory cells to reverse autoimmune neurodegenerative disease.
    J Neuroimmunol. 2018;324:100-114.
    PubMed     Abstract available


  321. ROCHA NP, Colpo GD, Bravo-Alegria J, Lincoln JA, et al
    Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis.
    J Neuroimmunol. 2018;326:45-48.
    PubMed     Abstract available


  322. WANG SX, Yang CL, Zhang M, Zhang P, et al
    Sulfatides ameliorate experimental autoimmune neuritis by suppressing Th1/Th17 cells.
    J Neuroimmunol. 2018;326:55-61.
    PubMed     Abstract available


  323. BOUXIN M, Schvartz B, Mestrallet S, Debrumetz A, et al
    Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature review.
    J Neuroimmunol. 2018;326:28-32.
    PubMed     Abstract available


  324. JENSEN PEH, Warnke C, Ingenhoven K, Piccoli L, et al
    Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
    J Neuroimmunol. 2018;326:19-27.
    PubMed     Abstract available


    October 2018
  325. RAMIREZ GA, Coletto LA, Bozzolo EP, Citterio L, et al
    The TRPC6 intronic polymorphism, associated with the risk of neurological disorders in systemic lupus erythematous, influences immune cell function.
    J Neuroimmunol. 2018;325:43-53.
    PubMed     Abstract available


  326. CAVAZZANA I, Alberici A, Bonomi E, Ottaviani R, et al
    Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?
    J Neuroimmunol. 2018;325:61-63.
    PubMed     Abstract available


  327. SAFIZADEH B, Hoshyar R, Mehrpour M, Eftekhar M, et al
    The role of expression and activity of 15-Lipoxygenase isoforms and related cytokines in patients with Multiple Sclerosis and healthy controls.
    J Neuroimmunol. 2018;325:32-42.
    PubMed     Abstract available


  328. ROSSETTI I, Zambusi L, Finardi A, Bodini A, et al
    Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;323:94-104.
    PubMed     Abstract available


  329. KVISTAD SS, Myhr KM, Holmoy T, Benth JS, et al
    Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.
    J Neuroimmunol. 2018;323:73-77.
    PubMed     Abstract available


  330. DUBEY D, Kothapalli N, McKeon A, Flanagan EP, et al
    Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction.
    J Neuroimmunol. 2018;323:62-72.
    PubMed     Abstract available


  331. DUBEY D, Hussain RZ, Miller-Little WA, Salter A, et al
    PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome.
    J Neuroimmunol. 2018;323:53-55.
    PubMed     Abstract available


  332. SLAVIN YN, Bo M, Caggiu E, Sechi G, et al
    High levels of antibodies against PtpA and PknG secreted by Mycobacterium avium ssp. paratuberculosis are present in neuromyelitis optica spectrum disorder and multiple sclerosis patients.
    J Neuroimmunol. 2018;323:49-52.
    PubMed     Abstract available


  333. AMORUSO A, Blonda M, D'Arrigo G, Grasso R, et al
    Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients.
    J Neuroimmunol. 2018;323:43-48.
    PubMed     Abstract available


  334. HOCAOGLU M, Durmus H, Ozkan B, Yentur SP, et al
    Increased costimulatory molecule expression of thymic and peripheral B cells and a sensitivity to IL-21 in myasthenia gravis.
    J Neuroimmunol. 2018;323:36-42.
    PubMed     Abstract available


  335. HAARMANN A, Hahnel L, Schuhmann MK, Buttmann M, et al
    Age-adjusted CSF beta2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
    J Neuroimmunol. 2018;323:19-27.
    PubMed     Abstract available


  336. SHAKERIAN L, Ghorbani S, Talebi F, Noorbakhsh F, et al
    MicroRNA-150 targets PU.1 and regulates macrophage differentiation and function in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;323:167-174.
    PubMed     Abstract available


  337. DEBNATH M, Nagappa M, Subbanna M, Sundaravadivel P, et al
    Th17 pathway signatures in a large Indian cohort of Guillain Barre syndrome.
    J Neuroimmunol. 2018;323:125-130.
    PubMed     Abstract available


  338. BLUM S, Ji Y, Pennisi D, Li Z, et al
    Genome-wide association study in Guillain-Barre syndrome.
    J Neuroimmunol. 2018;323:109-114.
    PubMed     Abstract available


  339. MOHAMMADZADEH A, Rad IA, Ahmadi-Salmasi B
    CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.
    J Neuroimmunol. 2018;323:105-108.
    PubMed     Abstract available


  340. KOSTIC M, Zivkovic N, Cvetanovic A, Stojanovic I, et al
    Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis.
    J Neuroimmunol. 2018;323:1-9.
    PubMed     Abstract available


  341. AQEL SI, Granitto MC, Nuro-Gyina PK, Pei W, et al
    Distinct roles for Blimp-1 in autoreactive CD4 T cells during priming and effector phase of autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;325:20-28.
    PubMed     Abstract available


  342. ALROUJI M, Manouchehrinia A, Gran B, Constantinescu CS, et al
    Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis.
    J Neuroimmunol. 2018 Oct 9. pii: S0165-5728(18)30130.
    PubMed     Abstract available


  343. SABRE L, Guptill JT, Russo M, Juel VC, et al
    Circulating microRNA plasma profile in MuSK+ myasthenia gravis.
    J Neuroimmunol. 2018 Oct 6. pii: S0165-5728(18)30383.
    PubMed     Abstract available


  344. TAVAKOLPOUR V, Shokri G, Naser Moghadasi A, Mozafari Nahavandi P, et al
    Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity.
    J Neuroimmunol. 2018 Oct 4. pii: S0165-5728(18)30173.
    PubMed     Abstract available


  345. SUGIMOTO K, Hiwasa T, Shibuya K, Hirano S, et al
    Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
    J Neuroimmunol. 2018;325:54-60.
    PubMed     Abstract available


    September 2018
  346. IWASA K, Yoshikawa H, Furukawa Y, Yamada M, et al
    Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis.
    J Neuroimmunol. 2018 Sep 27. pii: S0165-5728(18)30353.
    PubMed     Abstract available


  347. CASTOLDI V, Marenna S, Santangelo R, d'Isa R, et al
    Optic nerve involvement in experimental autoimmune encephalomyelitis to homologous spinal cord homogenate immunization in the dark agouti rat.
    J Neuroimmunol. 2018;325:1-9.
    PubMed     Abstract available


  348. JAFARZADEH A, Nemati M
    Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties.
    J Neuroimmunol. 2018;324:54-75.
    PubMed     Abstract available


  349. MCWILLIAM O, Sellebjerg F, Marquart HV, von Essen MR, et al
    B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTalpha and TGFbeta1 response.
    J Neuroimmunol. 2018 Sep 7. pii: S0165-5728(18)30276.
    PubMed     Abstract available


    August 2018
  350. SALAPA HE, Johnson C, Hutchinson C, Popescu BF, et al
    Dysfunctional RNA binding proteins and stress granules in multiple sclerosis.
    J Neuroimmunol. 2018 Aug 29. pii: S0165-5728(18)30377.
    PubMed     Abstract available


  351. FENOGLIO C, Oldoni E, Serpente M, De Riz MA, et al
    LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients.
    J Neuroimmunol. 2018 Aug 27. pii: S0165-5728(18)30259.
    PubMed     Abstract available


  352. HOU H, Cao R, Quan M, Sun Y, et al
    Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
    J Neuroimmunol. 2018;324:26-34.
    PubMed     Abstract available


  353. MORIGUCHI K, Miyamoto K, Fukumoto Y, Kusunoki S, et al
    4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice.
    J Neuroimmunol. 2018;323:131-135.
    PubMed     Abstract available


  354. CHEDRAWE MAJ, Holman SP, Lamport AC, Akay T, et al
    Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2018;321:72-82.
    PubMed     Abstract available


  355. FEKI S, Gargouri S, Mejdoub S, Dammak M, et al
    The intrathecal polyspecific antiviral immune response (MRZ reaction): A potential cerebrospinal fluid marker for multiple sclerosis diagnosis.
    J Neuroimmunol. 2018;321:66-71.
    PubMed     Abstract available


  356. FAGONE P, Mazzon E, Chikovani T, Saraceno A, et al
    Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis.
    J Neuroimmunol. 2018;321:41-48.
    PubMed     Abstract available


  357. LAI W, Kinoshita M, Peng A, Li W, et al
    Does pregnancy affect women with multiple sclerosis? A prospective study in Western China.
    J Neuroimmunol. 2018;321:24-28.
    PubMed     Abstract available


  358. MOHAJER B, Abbasi N, Pishgar F, Abdolalizadeh A, et al
    HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis.
    J Neuroimmunol. 2018;321:117-124.
    PubMed     Abstract available


    July 2018
  359. MIYAKE S, Yamamura T
    Gut environmental factors and multiple sclerosis.
    J Neuroimmunol. 2018 Jul 27. pii: S0165-5728(17)30414.
    PubMed     Abstract available


  360. NAKAMURA R, Makino T, Hanada T, Terakawa M, et al
    Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2018;320:64-75.
    PubMed     Abstract available


  361. KARAMPOOR S, Zahednasab H, Etemadifar M, Keyvani H, et al
    The levels of soluble forms of CD21 and CD83 in multiple sclerosis.
    J Neuroimmunol. 2018;320:11-14.
    PubMed     Abstract available


    June 2018
  362. HAASE S, Wilck N, Kleinewietfeld M, Muller DN, et al
    Sodium chloride triggers Th17 mediated autoimmunity.
    J Neuroimmunol. 2018 Jun 30. pii: S0165-5728(17)30512.
    PubMed     Abstract available


  363. SABERI R, Sharif M, Sarvi S, Aghayan SA, et al
    Is Toxoplasma gondii playing a positive role in multiple sclerosis risk? A systematic review and meta-analysis.
    J Neuroimmunol. 2018 Jun 22. pii: S0165-5728(17)30579.
    PubMed     Abstract available


  364. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
    Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    J Neuroimmunol. 2018;319:9-12.
    PubMed    


  365. SERIZAWA K, Tomizawa-Shinohara H, Magi M, Yogo K, et al
    Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:71-79.
    PubMed     Abstract available


  366. TIJERO B, Del Pino R, Perez-Concha T, Acera MA, et al
    Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.
    J Neuroimmunol. 2018;319:68-70.
    PubMed     Abstract available


  367. YOSHIKURA N, Kimura A, Fukata M, Fukata Y, et al
    Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
    J Neuroimmunol. 2018;319:63-67.
    PubMed     Abstract available


  368. HIRATSUKA D, Furube E, Taguchi K, Tanaka M, et al
    Remyelination in the medulla oblongata of adult mouse brain during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:41-54.
    PubMed     Abstract available


  369. AKAISHI T, Takahashi T, Nakashima I
    Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    J Neuroimmunol. 2018;319:37-40.
    PubMed     Abstract available


  370. FAGONE P, Mazzon E, Cavalli E, Bramanti A, et al
    Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences.
    J Neuroimmunol. 2018 Jun 15. pii: S0165-5728(18)30141.
    PubMed     Abstract available


    May 2018
  371. DUPREE JL, Feinstein DL
    Influence of diet on axonal damage in the EAE mouse model of multiple sclerosis.
    J Neuroimmunol. 2018 May 20. pii: S0165-5728(18)30104.
    PubMed     Abstract available


  372. BREUER J, Loser K, Mykicki N, Wiendl H, et al
    Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?
    J Neuroimmunol. 2018 May 18. pii: S0165-5728(17)30478.
    PubMed     Abstract available


  373. CHU F, Shi M, Zheng C, Shen D, et al
    The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;318:1-7.
    PubMed     Abstract available


  374. SABRE L, Maddison P, Sadalage G, Ambrose PA, et al
    Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.
    J Neuroimmunol. 2018 May 8. pii: S0165-5728(18)30122.
    PubMed     Abstract available


    April 2018
  375. DUBEY D, Hinson SR, Jolliffe EA, Zekeridou A, et al
    Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1year.
    J Neuroimmunol. 2018 Apr 27. pii: S0165-5728(18)30160.
    PubMed     Abstract available


  376. CASTANEDA-MORENO VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, et al
    MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593.
    PubMed     Abstract available


  377. YAN J, Winterford CM, Catts VS, Pat BK, et al
    Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis.
    J Neuroimmunol. 2018 Apr 6. pii: S0165-5728(17)30536.
    PubMed     Abstract available


  378. LI J, Qiu D, Chen Z, Du W, et al
    miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells.
    J Neuroimmunol. 2018 Apr 4. pii: S0165-5728(18)30166.
    PubMed     Abstract available


    March 2018
  379. ZAGORITI Z, Lagoumintzis G, Perroni G, Papathanasiou G, et al
    Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?
    J Neuroimmunol. 2018 Mar 17. pii: S0165-5728(17)30559.
    PubMed     Abstract available


  380. ALLENDER E, Deol H, Schram S, Maheras KJ, et al
    Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2018 Mar 10. pii: S0165-5728(17)30466.
    PubMed     Abstract available


  381. PAUNOVIC V, Petrovic IV, Milenkovic M, Janjetovic K, et al
    Autophagy-independent increase of ATG5 expression in T cells of multiple sclerosis patients.
    J Neuroimmunol. 2018 Mar 5. pii: S0165-5728(17)30538.
    PubMed     Abstract available


  382. SMITH PA, Schmid C, Zurbruegg S, Jivkov M, et al
    Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    J Neuroimmunol. 2018 Mar 3. pii: S0165-5728(17)30519.
    PubMed     Abstract available


  383. ASHTARI F, Esmaeil N, Mansourian M, Poursafa P, et al
    An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
    J Neuroimmunol. 2018 Mar 2. pii: S0165-5728(18)30019.
    PubMed     Abstract available


    February 2018
  384. MONTEIRO A, Cruto C, Rosado P, Martinho A, et al
    Characterization of circulating gamma-delta T cells in relapsing vs remission multiple sclerosis.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30533.
    PubMed     Abstract available


  385. BARBOUR M, Wood R, Hridi SU, Wilson C, et al
    The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30457.
    PubMed     Abstract available


  386. ROZMILOWSKA IM, Adamczyk-Sowa MH
    What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?
    J Neuroimmunol. 2018;315:50-57.
    PubMed    


  387. KUHN I, Rogosch T, Schindler TI, Tackenberg B, et al
    Serum titers of autoantibodies against alpha-synuclein and tau in child- and adulthood.
    J Neuroimmunol. 2018;315:33-39.
    PubMed     Abstract available


  388. GEORGE JD, Kim E, Spain R, Bourdette D, et al
    Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2018;315:24-27.
    PubMed     Abstract available


  389. IP PP, Chung CY, Chang CC, Lee YF, et al
    Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets.
    J Neuroimmunol. 2018 Feb 8. pii: S0165-5728(17)30498.
    PubMed     Abstract available


    January 2018
  390. LIU C, Liu H, Jin H, Yue X, et al
    Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.
    J Neuroimmunol. 2018 Jan 31. pii: S0165-5728(17)30560.
    PubMed     Abstract available


  391. HOR JY, Lim TT, Cheng MC, Chia YK, et al
    Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy.
    J Neuroimmunol. 2018 Jan 30. pii: S0165-5728(17)30491.
    PubMed     Abstract available


  392. RAHMAN MI, Jahan I, Khalid MM, Jahan I, et al
    CD1A and CD1E gene polymorphisms are not associated with susceptibility to Guillain-Barre syndrome in the Bangladeshi population.
    J Neuroimmunol. 2018;314:8-12.
    PubMed     Abstract available


  393. MEYER SAUTEUR PM, Huizinga R, Tio-Gillen AP, Drenthen J, et al
    Intrathecal antibody responses to GalC in Guillain-Barre syndrome triggered by Mycoplasma pneumoniae.
    J Neuroimmunol. 2018;314:13-16.
    PubMed     Abstract available


  394. LOSHAJ-SHALA A, Colzani M, Brezovska K, Poceva Panovska A, et al
    Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barre syndrome.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30422.
    PubMed     Abstract available


  395. VOGRIG A, Pauletto G, Belgrado E, Pegolo E, et al
    Effect of thymectomy on refractory autoimmune status epilepticus.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30485.
    PubMed     Abstract available


  396. LV J, Li L, Li W, Ji K, et al
    Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(18)30015.
    PubMed     Abstract available


  397. BAULINA N, Kulakova O, Kiselev I, Osmak G, et al
    Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
    J Neuroimmunol. 2018 Jan 5. pii: S0165-5728(17)30447.
    PubMed     Abstract available


  398. MASUDA H, Mori M, Umehara K, Furihata T, et al
    Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30562.
    PubMed     Abstract available


  399. OZKUL C, Guclu-Gunduz A, Irkec C, Fidan I, et al
    Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30484.
    PubMed     Abstract available


    December 2017
  400. DETRICK B, Gangaputra S, Palsgrove DN, Heaney CD, et al
    Elevated serum levels of IL-6 and CXCL9 in autoimmune retinopathy (AIR) patients.
    J Neuroimmunol. 2017 Dec 29. pii: S0165-5728(17)30269.
    PubMed     Abstract available


  401. IMITOLA J, Rasouli J, Watanabe F, Mahajan K, et al
    Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.
    J Neuroimmunol. 2017 Dec 22. pii: S0165-5728(17)30304.
    PubMed     Abstract available


  402. ROLLA S, De Mercanti SF, Bardina V, Horakova D, et al
    Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
    J Neuroimmunol. 2017;313:89-91.
    PubMed     Abstract available


  403. BHAT R, Mahapatra S, Axtell RC, Steinman L, et al
    Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.
    J Neuroimmunol. 2017;313:77-81.
    PubMed     Abstract available


  404. TAYLOR JM
    Tissue resident macrophages are sufficient for demyelination during peripheral nerve myelin induced experimental autoimmune neuritis?
    J Neuroimmunol. 2017;313:69-76.
    PubMed     Abstract available


  405. LI R, Sun X, Shu Y, Wang Y, et al
    Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients.
    J Neuroimmunol. 2017;313:56-60.
    PubMed     Abstract available


  406. GILLI F, Royce DB, DiSano KD, Pachner AR, et al
    Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;313:34-40.
    PubMed     Abstract available


  407. LIU J, Lian Z, Chen H, Shi Z, et al
    Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: A systematic review and meta-analysis.
    J Neuroimmunol. 2017;313:25-33.
    PubMed     Abstract available


  408. AKAISHI T, Kaneko K, Himori N, Takeshita T, et al
    Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2017;313:10-15.
    PubMed     Abstract available


  409. GLENN JD, Xue P, Whartenby KA
    Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Dec 8. pii: S0165-5728(17)30303.
    PubMed     Abstract available


  410. BANSI J, Koliamitra C, Bloch W, Joisten N, et al
    Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training.
    J Neuroimmunol. 2017 Dec 6. pii: S0165-5728(17)30420.
    PubMed     Abstract available


    November 2017
  411. KIM MJ, Lim JY, Park SA, Park SI, et al
    Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis.
    J Neuroimmunol. 2017 Nov 29. pii: S0165-5728(17)30134.
    PubMed     Abstract available


  412. MONTELEONE F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, et al
    Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.
    J Neuroimmunol. 2017 Nov 20. pii: S0165-5728(17)30179.
    PubMed     Abstract available


  413. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Corrigendum to Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders" [J. Neuroimmunol. 310. (2017) 150-157].
    J Neuroimmunol. 2017;312:66.
    PubMed    


  414. WANG Y, Zhang W, Yin J, Lu Q, et al
    Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
    J Neuroimmunol. 2017;312:59-65.
    PubMed     Abstract available


  415. HESSELMARK E, Bejerot S
    Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel.
    J Neuroimmunol. 2017;312:31-37.
    PubMed     Abstract available


  416. SVEINSSON O, Granqvist M, Forslin Y, Blennow K, et al
    Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.
    J Neuroimmunol. 2017;312:15-18.
    PubMed     Abstract available


  417. ROLF L, Muris AH, Theunissen R, Hupperts R, et al
    Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
    J Neuroimmunol. 2017 Nov 10. pii: S0165-5728(17)30208.
    PubMed     Abstract available


  418. MAZDEH M, Moradi N, Khoshroo E, Shayesteh Z, et al
    Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    J Neuroimmunol. 2017 Nov 8. pii: S0165-5728(17)30405.
    PubMed     Abstract available


    October 2017
  419. LIU W, Zhu M, Yu Z, Yin D, et al
    Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Oct 31. pii: S0165-5728(17)30191.
    PubMed     Abstract available


  420. PALTERER B, Brugnolo F, Sieni E, Barilaro A, et al
    Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation.
    J Neuroimmunol. 2017;311:10-13.
    PubMed     Abstract available


  421. LEI HW, Wang JY, Dang QJ, Yang F, et al
    Neuropsychiatric involvement in lupus is associated with the Nogo-a/NgR1 pathway.
    J Neuroimmunol. 2017;311:22-28.
    PubMed     Abstract available


  422. HUANG ZL, Pandya D, Banta DK, Ansari MS, et al
    Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis.
    J Neuroimmunol. 2017;311:40-48.
    PubMed     Abstract available


    September 2017
  423. FERNANDEZ HURST N, Zanetti SR, Baez NS, Bibolini MJ, et al
    Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Sep 30. pii: S0165-5728(17)30297.
    PubMed     Abstract available


  424. MERKER M, Eichler S, Herrmann AM, Wiendl H, et al
    Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 21. pii: S1521-6616(17)30639.
    PubMed     Abstract available


  425. BADIHIAN S, Manouchehri N, Badihian N
    More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 18. pii: S0165-5728(17)30401.
    PubMed    


  426. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Abstract available


  427. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Abstract available


  428. JAHAN I, Ahammad RU, Farzana KS, Khalid MM, et al
    Tumor necrosis factor-alpha -863C/A polymorphism is associated with Guillain-Barre syndrome in Bangladesh.
    J Neuroimmunol. 2017;310:46-50.
    PubMed     Abstract available


  429. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Abstract available


  430. HAITAO R, Huiqin L, Tao Q, Xunzhe Y, et al
    Autoimmune encephalitis associated with vitiligo?
    J Neuroimmunol. 2017;310:14-16.
    PubMed     Abstract available


  431. DELGADO-GARCIA G, Corona-Vazquez T
    IgG4-related disease and IgG4-mediated neurological autoimmune disorders: One and the same?
    J Neuroimmunol. 2017;310:129-130.
    PubMed    


  432. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Abstract available


  433. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.
    J Neuroimmunol. 2017;310:51-59.
    PubMed     Abstract available


  434. ZHU DS, Yu L, Li M, Han L, et al
    High serum creatinine is associated with reduction of vision impaired in patients with NMOSD.
    J Neuroimmunol. 2017;310:32-37.
    PubMed     Abstract available


  435. WANG J, Yang C, Zhao Q, Zhu Z, et al
    Microglia activation induced by serum of SLE patients.
    J Neuroimmunol. 2017;310:135-142.
    PubMed     Abstract available


  436. LINDSEY JW
    Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
    J Neuroimmunol. 2017;310:131-134.
    PubMed     Abstract available


  437. ALVARENGA MP, Fernandez O, Leyva L, Campanella L, et al
    The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.
    J Neuroimmunol. 2017;310:1-7.
    PubMed     Abstract available


  438. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Abstract available


  439. LAZARIDIS K, Dalianoudis I, Baltatzidi V, Tzartos SJ, et al
    Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2017 Sep 6. pii: S0165-5728(17)30332.
    PubMed     Abstract available


    August 2017
  440. YESHOKUMAR AK, Gordon-Lipkin E, Arenivas A, Cohen J, et al
    Neurobehavioral outcomes in autoimmune encephalitis.
    J Neuroimmunol. 2017 Aug 31. pii: S0165-5728(17)30274.
    PubMed     Abstract available


  441. ALVAREZ BRAVO G, Yusta Izquierdo A, Carvalho Monteiro G, Sanchez I, et al
    Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy.
    J Neuroimmunol. 2017 Aug 19. pii: S0165-5728(17)30265.
    PubMed     Abstract available


  442. LIU RT, Zhang P, Yang CL, Pang Y, et al
    ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.
    J Neuroimmunol. 2017 Aug 18. pii: S0165-5728(17)30182.
    PubMed     Abstract available


  443. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Abstract available


  444. WALLWITZ U, Brock S, Schunck A, Wildemann B, et al
    From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.
    J Neuroimmunol. 2017;309:77-81.
    PubMed     Abstract available


  445. PITAROKOILI K, Kohle F, Motte J, Fatoba O, et al
    Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis.
    J Neuroimmunol. 2017;309:58-67.
    PubMed     Abstract available


  446. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Abstract available


  447. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Abstract available


  448. MATHEY EK, Garg N, Park SB, Nguyen T, et al
    Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
    J Neuroimmunol. 2017;309:41-46.
    PubMed     Abstract available


  449. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Abstract available


  450. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Abstract available


  451. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Abstract available


  452. LI X, Lin J, Pan S, Weng Y, et al
    Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;309:68-71.
    PubMed     Abstract available


  453. KON T, Ueno T, Suzuki C, Nunomura J, et al
    Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer.
    J Neuroimmunol. 2017;309:38-40.
    PubMed     Abstract available


  454. LIU J, Shi Z, Lian Z, Chen H, et al
    Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population.
    J Neuroimmunol. 2017;309:23-30.
    PubMed     Abstract available


  455. HENDRICKX DAE, van Eden CG, Schuurman KG, Hamann J, et al
    Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology.
    J Neuroimmunol. 2017;309:12-22.
    PubMed     Abstract available


  456. SUCHDEV K, Razmjou S, Venkatachalam P, Khan OA, et al
    Late onset neuromyelitis optica mimicking an acute stroke in an elderly patient.
    J Neuroimmunol. 2017;309:1-3.
    PubMed     Abstract available


  457. AHMAD SF, Ansari MA, Nadeem A, Bakheet SA, et al
    Adenosine A2A receptor signaling affects IL-21/IL-22 cytokines and GATA3/T-bet transcription factor expression in CD4+ T cells from a BTBR T+ Itpr3tf/J mouse model of autism.
    J Neuroimmunol. 2017 Aug 9. pii: S0165-5728(17)30253.
    PubMed     Abstract available


  458. WILDNER P, Selmaj KW
    Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
    J Neuroimmunol. 2017 Aug 2. pii: S0165-5728(17)30263.
    PubMed     Abstract available


    July 2017
  459. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Abstract available


    June 2017
  460. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Abstract available


  461. ASMAIL A, Kesler A, Drory VE, Kolb H, et al
    Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel.
    J Neuroimmunol. 2017;307:47-52.
    PubMed     Abstract available


  462. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Abstract available


  463. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Abstract available


  464. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Abstract available


  465. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Abstract available


  466. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Abstract available


  467. BARROS PO, Dias ASO, Kasahara TM, Ornelas AMM, et al
    Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients.
    J Neuroimmunol. 2017;307:82-90.
    PubMed     Abstract available


    May 2017
  468. JING S, Song Y, Song J, Pang S, et al
    Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074.
    PubMed     Abstract available


  469. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Abstract available


  470. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Abstract available


  471. CONSTANTINESCU R, Krysl D, Andren K, Asztely F, et al
    Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.
    J Neuroimmunol. 2017;306:25-30.
    PubMed     Abstract available


  472. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Abstract available


  473. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Abstract available


  474. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Abstract available


    April 2017
  475. AGLIARDI C, Guerini FR, Zanzottera M, Bolognesi E, et al
    Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort.
    J Neuroimmunol. 2017;305:92-95.
    PubMed     Abstract available


  476. DENG B, Liu XN, Li X, Zhang X, et al
    Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome.
    J Neuroimmunol. 2017;305:84-91.
    PubMed     Abstract available


  477. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.
    J Neuroimmunol. 2017;305:59-67.
    PubMed     Abstract available


  478. ZHOU L, Huang Y, Li H, Fan J, et al
    MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients.
    J Neuroimmunol. 2017;305:19-28.
    PubMed     Abstract available


  479. SCOTT TF
    Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.
    J Neuroimmunol. 2017;305:162-166.
    PubMed     Abstract available


  480. PAWLAK-ADAMSKA E, Nowak O, Karabon L, Pokryszko-Dragan A, et al
    PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.
    J Neuroimmunol. 2017;305:115-127.
    PubMed     Abstract available


  481. KIMURA A, Takemura M, Saito K, Serrero G, et al
    Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:175-181.
    PubMed     Abstract available


    February 2017
  482. PANT AB, Wang Y, Mielcarz DW, Kasper EJ, et al
    Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    J Neuroimmunol. 2017;303:22-30.
    PubMed     Abstract available


  483. LAZARIDIS K, Baltatzidi V, Trakas N, Koutroumpi E, et al
    Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.
    J Neuroimmunol. 2017;303:13-21.
    PubMed     Abstract available


  484. WARNECKE A, Musunuri S, N'diaye M, Sandalova T, et al
    Nitration of MOG diminishes its encephalitogenicity depending on MHC haplotype.
    J Neuroimmunol. 2017;303:1-12.
    PubMed     Abstract available


    January 2017
  485. ZHANGBAO J, Zhou L, Li X, Cai T, et al
    The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.
    J Neuroimmunol. 2017;302:49-55.
    PubMed     Abstract available


    December 2016
  486. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Abstract available


    November 2016
  487. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: